KeraVision
This article was originally published in The Gray Sheet
Executive Summary
Ad campaign for Intacs intrastromal corneal ring segments to treat mild nearsightedness commences the week of May 15 in 20 U.S. cities. The device gained FDA approval last year (1"The Gray Sheet" April 19, 1999, p. 12). The company plans to spend up to $5 mil. for radio, print and direct mail ads in the consumer campaign, the company says in a May 18 release